-

Catalent, Inc. to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today announced that members of its executive leadership team will virtually present at the Morgan Stanley 19th Annual Global Healthcare Conference at 1:15 a.m. ET on September 9, 2021.

A live webcast of the presentation will be accessible at http://investor.catalent.com and will be available for replay following the event.

About Catalent, Inc.
Catalent Inc. [NYSE: CTLT], an S&P 500® company, is the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products. With almost 90 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance, and ensuring reliable global clinical and commercial product supply. Catalent’s workforce exceeds 17,000 people, including more than 2,500 scientists and technicians, at more than 50 facilities on four continents, and in fiscal year 2021, it generated $4 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, please visit www.catalent.com.

Contacts

Investor Contact:
Paul Surdez, Catalent, Inc.
(732) 537-6325
investors@catalent.com

Catalent, Inc.

NYSE:CTLT

Release Versions

Contacts

Investor Contact:
Paul Surdez, Catalent, Inc.
(732) 537-6325
investors@catalent.com

More News From Catalent, Inc.

Catalent and Mantra™ Announce Commercial Supply Agreement for Single-Serve Oral Gel Portfolio

TAMPA, Fla. & WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, and Mantra™, a consumer health company developing single-serve, over the counter (OTC) oral gel products for everyday relief, today announced a commercial supply agreement for Mantra’s oral gel product platform. Catalent will provide formulation development, commercial manufacturing and pa...

Catalent Launches Accelerated Gene-to-Drug Substance Program for Complex Molecules in the U.S.

TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced the U.S. launch of an accelerated gene-to-drug substance program for complex biologics, designed to help developers move bispecifics, multispecifics and other next-generation molecules from gene sequence to drug substance in 10 months. The program builds on Catalent's Rapid Antibody offering for t...

Catalent Completes Successful Debt Refinancing to Support Continued Growth and Innovation

TAMPA, Fla.--(BUSINESS WIRE)--Catalent has completed a significant debt refinancing transaction to support its future growth while reducing its annual interest expenses....
Back to Newsroom